SETD2 and cancer: In this regard, in cancer cells HIF-1 and HIF-2 have been reported to downregulate the expression of proliferator-activated receptor-γ coactivator-1α (PGC-1α), carnitine palmitoyltransferase 1A (CPT1A), and medium- and long-chain acyl-COA dehydrogenases (MACD and LACD), which are involved in β-oxidation inhibition [63,64].